3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

US11339156B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• MSD R&D (China) Co. Ltd. · CN

Inventors

• John J. Acton, III · Cranford, US
• Jianming Bao · Scotch Plains, US
• Qiaolin Deng · Edison, US
• Melissa Egbertson · Ambler, US
• Ronald D. Ferguson · Scotch Plains, US
• Xiaolei Gao · Bound Brook, US
• Scott T. Harrison · Cheltenham, US
• Timothy J. Henderson · Natick, US
• Sandra Lee Knowles · Princeton, US
• Chunsing Li · Shanghai, CN
• Michael Man-Chu Lo · Rahway, US
• Robert Mazzola · Stewartsville, US
• Meng Na · Shanghai, CN
• Michael T. Rudd · Collegeville, US
• Oleg B. Selyutin · Princeton Colonial Park, US
• David M. Tellers · Lansdale, US
• Ling Tong · Hackettstown, US
• Fengqi Zhang · Gaorihan, CN
• Takao Suzuki · Shanghai, CN

Key dates

• Filing date: Jun 22, 2018
• Grant date: May 24, 2022
• Expiry date: Mar 3, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.